This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Abbott Hits Targets, Backs '09 Forecast

Stocks in this article: ABT EYE

Updated from 8:48 a.m. EST

Abbott Laboratories (ABT) matched Wall Street's fourth-quarter earnings estimates Wednesday and reiterated its forecast for double-digit profit growth in 2009.

The diagnostics, medical devices and drug maker reported net income for the fourth quarter of $1.54 billion, or 98 cents a share, compared with net income of $1.2 billion, or 77 cents a share, in the year-ago quarter.

Excluding special items, Abbott reported a 14% increase in earnings per share to $1.06 in the fourth quarter, in line with the Street's consensus estimate.

Fourth-quarter revenue rose 10% to $7.95 billion, essentially matching the consensus analyst forecast of $8 billion. Abbott reported revenue of $7.22 billion in the year-ago quarter.

Abbott reiterated its 2009 earnings forecast, first offered Jan. 12, in the range of $3.65 to $3.70 a share on both a GAAP and adjusted basis. At the time, Wall Street was expecting earnings of $3.66 a share.

The midpoint of Abbott's guidance represents 10% growth over 2008 adjusted earnings of $3.32 a share.

Abbott's 2009 earnings outlook includes the company's planned $2.8 billion purchase of eye care company Advanced Medical Optics (EYE).

The bullish forecast offered by Abbott management stands in contrast with diversified health care giant Johnson & Johnson (JNJ), which said Tuesday that this year's revenue would fall from the reported 2008 level, the company's first annual revenue decline in 75 years. Johnson & Johnson blamed the recession, which is forcing consumers to spend less on health care products, both prescription drugs and consumer products.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs